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a r t I C l e S
Mutations in the ubiquitin E3 ligase PARKIN (also known as PARK2) are an important cause of familial Parkinson's disease 1, 2 . In general, the majority of mutations in PARKIN result in a loss of E3 ligase activity [3] [4] [5] . In the more common sporadic form of Parkinson's disease, there may be a loss of parkin function as a result of S-nitrosylation, oxidative and dopaminergic stress, and phosphorylation by the stressactivated kinase c-Abl [6] [7] [8] [9] [10] [11] [12] [13] . Parkin is a multifunctional E3 ligase that ubiquitinates proteins using different ubiquitin lysine linkages. Monoubiquitination of parkin substrates is thought to lead to alterations in receptor trafficking and cell signaling 5 . Polyubiquitination via lysine 63 or 29 linkages may be involved in inclusion body formation and autophagy 14, 15 . Parkin substrates that are polyubiquitinated via lysine 48 linkages are degraded by the ubiquitin proteosome system. The loss of parkin function in Parkinson's disease would be expected to impair the ubiquitin proteasome system clearance of lysine 48 substrates and interfere with other parkin E3 ligase functions 16 . Given that parkin is inactivated in familial Parkinson's disease with PARKIN mutations, sporadic Parkinson's disease, Parkin −/− mice (also known as Park2 −/− ) and following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication in mice 9 , substrates elevated in all four conditions are candidates for parkin-mediated polyubiquitination via lysine 48 linkages and subsequent ubiquitin proteosome degradation.
AIMP2, also known as JTV-1 or P38, is a parkin substrate that is present in Lewy body inclusions of Parkinson's disease substantia nigra 17, 18 . AIMP2 is a strong candidate as a pathogenic parkin substrate that accumulates in Parkinson's disease as a result of parkin inactivation, as AIMP2 levels are elevated in the ventral midbrain in Parkin −/− mice and post-mortem brain from patients with PARKIN mutations or sporadic Parkinson's disease 7, 9, 18 . AIMP2 also accumulates in the MPTP model of Parkinson's disease, consistent with the notion that parkin is inactivated following MPTP intoxication 9 . If accumulation of a parkin substrate is important in the pathogenesis of Parkinson's disease, transgenic overexpression in an animal model should lead to an age-dependent progressive degeneration of dopamine neurons.
To explore a potential biologic mechanism for AIMP2 and to validate its role as a pathogenic substrate in Parkinson's disease, we generated a tetracycline-regulated inducible transgenic mouse model 19, 20 of AIMP2 overexpression. AIMP2 overexpression at levels seen in Parkinson's disease leads to an age-dependent degeneration of dopaminergic neurons that causes striatal dopaminergic deficits and impairment of motor coordination. AIMP2 toxicity is not mediated by its canonical function because gross protein translation is normal. Unexpectedly, AIMP2 directly activates PARP1, which is important for the DNA damage response through poly(ADP-ribosyl)ation of a r t I C l e S PARP1 itself and chromatin-associated proteins 8, 21 . Excessive activation of PARP1 kills cells via the formation of poly(ADP-ribose) (PAR) polymer in a cell death mechanism known as parthanatos 22 . During parthanatos, PAR polymer translocates from the nucleus to the mitochondria and binds apoptosis-inducing factor (AIF). PAR polymer binding to AIF facilitates the release of AIF from the mitochondria and translocation to the nucleus followed by large-scale DNA fragmentation and nuclear condensation leading to the execution phase of parthanatos 23, 24 . Knockout or inhibition of PARP1 completely prevents the degeneration of dopaminergic neurons resulting from AIMP2 overexpression. Thus, AIMP2-mediated dopaminergic cell death is mediated by parthanatos, suggesting that PARP1 inhibition may effectively delay the progression of Parkinson's disease.
RESULTS

Generation of inducible transgenic AIMP2 mice
To investigate whether AIMP2 causes neuronal degeneration in vivo, we generated a conditional transgenic mouse model in which the expression of a C-terminal FLAG-tagged human AIMP2 is under the control of a tetracycline-responsive regulator (Fig. 1a) . We identified 29 founders expressing TetP-AIMP2 via PCR screening for the tetracycline promoter ( Supplementary Fig. 1a,b) . Five of the highest copy number male founder mice were crossed with Camk2a-tTA transgenic mice 25 , and mice expressing both CamKIIα-tTA and AIMP2 were identified by PCR (Supplementary Fig. 1c) .
Expression of AIMP2 was detected in ventral midbrain and cortex and compared with that of littermate controls expressing either Camk2a-tTA or TetP-AIMP2 alone. The overexpression of AIMP2 was tetracycline responsive, as doxycycline administration attenuated the upregulation of AIMP2 (Supplementary Fig. 1d ). Line 630 overexpressed AIMP2 ~14-fold in the cortex and ~4-fold in the ventral midbrain compared with controls (Fig. 1b,c) . Line 634 overexpressed AIMP2 ~4-fold in the cortex and ~3-fold in the ventral midbrain (Fig. 1b,c) . Line 323 overexpressed AIMP2 ~5-fold in the cortex and ~2-fold in the ventral midbrain (Fig. 1b,c) . As line 630 expressed the highest levels of AIMP2, we selected it for detailed characterization. Western blot analysis indicates that AIMP2 is overexpressed 4-15-fold throughout the forebrain, olfactory bulb, ventral midbrain and cerebellum with no overexpression in the pons and medulla (Fig. 1d,e) . Immunohistochemistry with an antibody to AIMP2 revealed that the majority of AIMP2 overexpression occurred in neurons (Fig. 1f) . To determine whether AIMP2 overexpression in the substantia nigra is localized to dopaminergic neurons, we performed colocalization studies with AIMP2 and tyrosine hydroxylase (Fig. 1g) . AIMP2 was overexpressed in the majority of tyrosine hydroxylasecontaining neurons in the substantia nigra (Fig. 1g) .
Selective dopaminergic degeneration in AIMP2 mice All lines of AIMP2 transgenic mice are viable and develop normally. AIMP2 transgenic mice and littermate control mice appeared to have comparable body weight for up to 3 months of age. Starting at 5 months of age, the AIMP2 mice gained less body weight than littermate controls and we observed a significant reduction in body weight at 14 and 20 months of age (P = 0.0000152 and P = 0.0092, respectively; Supplementary Fig. 2) . To determine the effect of AIMP2 expression on dopamine neuronal viability, we monitored tyrosine hydroxylase immunoreactivity and Nissl staining in the substantia nigra zona compacta (SNpc) using unbiased stereologic methods. At 2-3 months of age, there was a trend toward a loss of tyrosine hydroxylase-positive and Nissl-stained neurons. At 8 months of age, there was a 37% loss of tyrosine hydroxylase-positive and Nissl-stained neurons in the SNpc that progressed to 53% at 20 months (Fig. 2a,b) . In addition, approximately 28% of dopamine neurons in the ventral tegmental area (VTA) had degenerated in AIMP2 transgenic mice by 20 months of age (Supplementary Fig. 3a) , consistent with the loss of VTA dopamine neurons in Parkinson's disease 26 . Thus, VTA dopamine neurons are less sensitive to AIMP2 toxicity than those in the SNpc, similar to the differential vulnerability of the SNpc and VTA dopamine neurons in Parkinson's disease 26 . To further confirm that dopamine neuronal loss in the SNpc depends on AIMP2 accumulation, we characterized another transgenic line expressing AIMP2 at lower levels (line 634). At 10 months of age, there was a significant loss of dopamine neurons in this second line of AIMP2 transgenic mice (21%, P = 0.016; Supplementary Fig. 3b,c) .
In the highest AIMP2-expressing line, no substantial loss of neurons was identified in other brain regions. In the cortex, which overexpressed AIMP2, ~14-fold there was a small reduction (10%) of neurons at 2 months of age, but there was no substantial difference in neuron number at 20 months of age between AIMP2 transgenic mice and age-matched littermate controls, suggesting that the degeneration of dopamine neurons induced by AIMP2 is selective (Fig. 2c,d ).
To evaluate whether there are other neuropathologic abnormalities, we examined the brains of AIMP2 mice and littermate controls for astrocytosis. In 20-month-old AIMP2 transgenic mice, there was a substantial increase in glial fibrillary acidic protein (GFAP) immunoreactivity in the substantia nigra, consistent with the loss of dopaminergic neurons (Fig. 2e) . There was no substantial difference in GFAP immunoreactivity in the cortex between the AIMP2 transgenic mice and age-matched littermate controls (Fig. 2e) . Western blot analyses of the levels of GFAP confirmed that there was a significant, greater than threefold and twofold, upregulation of GFAP in the substantia nigra of 20-month-old (P = 0.00172) and 3-month-old (P = 0.0217) AIMP2 transgenic mice, respectively, but no change in the cortex (Fig. 2f,g ).
Behavioral and dopaminergic deficits in AIMP2 mice
We examined the motor function of AIMP2 transgenic mice by rotarod and open field testing. AIMP2 transgenic mice performed normally in the open field test compared with age-matched littermate controls at 8 and 20 months of age (Fig. 3a) . In an accelerating rotarod procedure, AIMP2 transgenic mice showed a progressive loss of their ability to remain on the rod compared with age-matched littermate controls (Fig. 3b) . In a dopamine-sensitive pole test, AIMP2 transgenic mice exhibited deficits in climbing down the pole as assessed at 20 months of age (time to ground in pole test, mean ± s.e.m.: control, 43.8 ± 11.2 s; transgenic, 97.9 ± 10.2 s; P < 0.05 determined by Mann-Whitney test, n = 13 control and 8 transgenic mice). High-performance liquid chromatography (HPLC) analysis of dopamine and its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), was performed to monitor dopaminergic integrity. At 3 months of age, AIMP2 transgenic mice showed a 20% reduction in dopamine, DOPAC and HVA compared with age-matched littermate controls. The loss of dopamine was progressive, with a 60% reduction of dopamine content at 20 months of age in the AIMP2 transgenic mice. DOPAC and HVA levels remained reduced at 20 months of age (Fig. 3c) .
Assessment of the (DOPAC + HVA)/dopamine ratio suggests that there is a trend toward increased dopamine metabolism in the AIMP2 transgenic mice (data not shown). Dopamine terminal density in the striatum was assessed in the AIMP2 transgenics compared with age-matched littermate controls. There was a 40% reduction of dopamine terminal density in 20-month-old AIMP2 transgenic npg a r t I C l e S mice ( Fig. 3d-f) . Taken together, these data indicate that expression of AIMP2 leads to an age-dependent loss of dopaminergic neurons that is accompanied by motor deficits.
AIMP2 accumulation leads to PARP1 activation
To explore the potential mechanism by which AIMP2 overexpression leads to neurodegeneration, we developed a conditional AIMP2 PC12 cell model 9 by expressing AIMP2 under the control of the tetracycline-responsive promoter (Supplementary Fig. 4a ). The canonical function of AIMP2 is in aminoacyl-tRNA synthesis, which is essential for peptide extension during protein synthesis 27 . To determine whether AIMP2 overexpression affects protein synthesis, we monitored 35 (g) Immunofluorescent images of AIMP2 (red) and tyrosine hydroxylase (TH, green) from AIMP2 transgenic and control mice. Bottom row, magnified view. Quantified data (c,e) are expressed as mean ± s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001, unpaired two-tailed Student's t test. β-actin was used as an internal loading control (b,d). Full-length blots are presented in Supplementary Figure 14. npg a r t I C l e S (e) Quantification of optical densities of d (control, n = 3; transgenic, n = 4). Optical density of the striatum was subtracted by background before normalization. Densitometric analysis was processed using ImageJ software. (f) High magnification of tyrosine hydroxylase-positive dopaminergic nerve fibers in the striatum. Quantified data (a-c,e) were expressed as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired two-tailed Student's t test (a,e), or Kruskal-Wallis ANOVA test (b,c). npg a r t I C l e S (Fig. 4a) . AIMP2 overexpression activated PARP and led to a 3.5-fold increase in PAR levels (relative levels, mean ± s.e.m.: mock, 1.4 ± 0.2; AIMP2, 3.9 ± 0.3; P < 0.01, determined by unpaired Student's t test) and a greater than fivefold increase in PARsylated PARP1 (relative levels, mean ± s.e.m.: mock, 1.2 ± 0.4; AIMP2, 6.1 ± 1.0; P < 0.05 determined by unpaired Student's t test) (Fig. 4b) . To determine whether AIMP2 interacts with PARP1 directly, we carried out co-immunoprecipitation experiments and found that immunoprecipitation of FLAG-AIMP2 in SH-SY5Y cells pulled down endogenous PARP1 (Fig. 4c) . In an immunopurified PARP1 pulldown assay, recombinant AIMP2 bound to immunopurified PARP1 (Fig. 4d) . Recombinant AIMP2-FLAG also pulled down recombinant PARP1 in an immunoprecipitation with an antibody to FLAG (Fig. 4e) . Taken together, these data indicate that the AIMP2 and PARP1 proteins interact.
Deletion analysis revealed that PARP1 interacted with amino acids 1-83 of AIMP2 (Supplementary Fig. 5a ) and AIMP2 interacted with the automodification domain of PARP1 (Supplementary Fig. 5b ). Although AIMP2 was primarily enriched in the post-nuclear fraction, there was also a smaller pool present in the nuclear fraction that was available to interact with PARP1, as determined by subcellular fractionation and monitored by AIMP2, the nuclear marker PARP1 and the mitochondrial marker manganese superoxide dismutase (MnSOD) immunoreactivity (Fig. 4f) . Confocal image analysis revealed that AIMP2 was primarily localized to the cytosol, but a small percentage was found in the nucleus (Fig. 4g) . In the ventral midbrain of AIMP2 transgenic mice, immunoprecipitated FLAG-AIMP2 pulled down PARP1 and immunoprecipitation of PARP1 pulled down FLAG-AIMP2 (Fig. 4h,i) . The interaction of AIMP2 and PARP1 in the ventral midbrain in vivo was also confirmed in transgenic line 322, which overexpressed AIMP2 at levels similar to the adult conditional Parkin −/− mouse brains ( Supplementary Figs. 6a and 7a,b) . To ascertain whether AIMP2 binding to PARP1 directly activates PARP1, we performed a PARP ribosylation activity assay in the presence of recombinant GST-AIMP2, using GST as a control. GST-AIMP2 significantly increased the ribosylation activity of PARP1 (P = 0.008, 0.032, 0.008 for 0.125, 0.25 and 1.0 units of PARP1, respectively; Fig. 4j ).
We then monitored the subcellular localization of AIMP2 in the ventral midbrain of AIMP2 transgenic mice versus age-matched littermate controls. AIMP2 was found in both the nuclear and post-nuclear fractions, as monitored by PARP1 and MnSOD immunoreactivity, respectively (Fig. 4k) . Accompanying the nuclear localization of npg a r t I C l e S AIMP2, there was an approximately 2.5-fold increase in the level of PAR (relative levels, mean ± s.e.m.: control, 1.1 ± 0.1; transgenic, 2.4 ± 0.3; P < 0.05 determined by unpaired Student's t test, n = 6 per group) in the ventral midbrain of AIMP2 transgenic mice as compared with age-matched littermate controls (Fig. 4l) . The association of overexpressed AIMP2 and nuclear PARP1 appeared to be region specific, as we failed to detect nuclear translocation of AIMP2 or interaction of AIMP2 and PARP1 in cortical tissues of AIMP2 transgenic mice (Supplementary Fig. 6b,c) . Consistent with these results, no significant change in PAR levels was observed in the cortex of AIMP2 transgenic mice versus age-matched control mice (P = 0.0577; Supplementary Fig. 8a,b) .
To further explore the AIMP2-PARP1 pathway, we treated SH-SY5Y cells with H 2 O 2 or N-methyl-N′-nitro-N′-nitrosoguanidine (MNNG), a DNA-damaging reagent and strong PARP1 activator. Following treatment with H 2 O 2 or MNNG, endogenous AIMP2 translocated into the nucleus (Supplementary Fig. 9a ), leading to a strong association with PARP1 and subsequent PAR production ( Supplementary  Fig. 9b ). Taken together, these data indicate that AIMP2 interacts with PARP1 in the nucleus, leading to PARP1 activation and PAR formation in dopaminergic neurons of the substantia nigra.
AIMP2 neurodegeneration occurs through parthanatos
Given that CamKIIα-tTA-driven expression of AIMP2 resulted in a broad expression of AIMP2 in the mouse forebrain and that the degeneration of dopamine neurons in the midbrain takes 8-20 months to occur, we sought to develop a conditional model in which AIMP2 overexpression is largely confined to the ventral midbrain and the loss of dopamine neurons occurs on a shorter timescale. We constructed an adeno-associated virus type 1 (AAV1) vector in which the chicken β-actin promoter drives tTA, and IRES2 zsGreen is used for monitoring expression (AAV1-tTA-IRESzsGreen; Supplementary Fig. 10a ). AAV1-tTA-IRES-zsGreen was stereotaxically injected into the ventral midbrain of TetP-AIMP2 transgenic mice or non-transgenic control mice (Fig. 5a) . The AAV1-tTA-IRES-zsGreen robustly transduced the ventral midbrain of non-transgenic mice, with a majority of dopaminergic neurons being transduced as monitored by colocalization of tyrosine hydroxylase immunostaining with zsGreen ( Supplementary  Fig. 10b ). We monitored AIMP2 levels 17 d after injection by immunoblot, and AIMP2 levels were increased by more than twofold (Fig. 5b,c) . To determine whether these mice exhibit comparable levels of AIMP2 expression as Parkin −/− mice, we assessed the level of AIMP2 in adult conditional Parkin −/− mice. AIMP2 was overexpressed approximately twofold in adult conditional Parkin −/− mice ( Supplementary Fig. 7a,b) . At 25 d post injection, there was a robust loss of tyrosine hydroxylase immunoreactivty in the substantia nigra zona compacta (Fig. 5d) . Unbiased stereologic analysis of tyrosine hydroxylase-immunoreactive and Nissl-stained neurons revealed a greater than 95% loss of dopamine neurons (Fig. 5e) . Consistent with the lack of cortical neurotoxicity in the AIMP2 transgenic mice, virally induced AIMP2 overexpression in the cortex of TetP-AIMP2 mice (at similar levels of overexpression of AIMP2 in the ventral midbrain) failed to activate PARP1 (Supplementary Fig. 11a-c) and there was no obvious degeneration of cortical neurons (Supplementary Fig. 11d,e) . npg a r t I C l e S To determine whether parthanatos is involved in AIMP2-induced dopamine cell loss, we monitored PARP1 activation 17 d after the AAV1-tTA-IRES-zsGreen injection. PAR levels were increased twofold (Fig. 5b,c) . We then crossed TetP-AIMP2 transgenic mice with Parp1 −/− mice to create TetP-AIMP2; Parp1 −/− mice ( Supplementary  Fig. 1e ). These TetP-AIMP2; Parp1 −/− mice were stereotaxically injected with AAV1-tTA-IRES-zsGreen, and dopamine cell loss was monitored and compared with that of TetP-AIMP2 mice with and without doxycycline treatment. AIMP2 induction and PARP1 activation were examined via western blot analysis using antibodies to AIMP2 and PAR (Fig. 5f) . AIMP2 induction was efficiently suppressed by doxycycline treatment in TetP-AIMP2 mice, and the elevation of PARsylation proteins in the injected side of TetP-AIMP2 was reduced to basal levels (Fig. 5f,g ). Knockout of PARP1 completely rescued the degeneration of dopamine neurons, similar to the absence of loss of dopamine neurons in the presence of doxycycline, which prevents the expression of AIMP2 (Fig. 5h,i) . PARP1 activation was monitored by PAR immunoreactivity in AAV1-tTA-IRES-zsGreeninjected TetP-AIMP2 transgenic mice and TetP-AIMP2; Parp1 −/− mice. There was an approximately twofold increase in PAR in the TetP-AIMP2 transgenic mice, and we found no increase in the TetP-AIMP2; Parp1 −/− mice (Fig. 5f,g ). As the injection was unilateral, we used amphetamine-induced rotation as a functional behavioral readout of dopaminergic degeneration. AIMP2 overexpression led to an eightfold increase in rotational behavior, consistent with a loss of dopamine neurons. Knockout of PARP1 prevented amphetamineinduced rotation, indicating that the dopamine neurons had been spared and were functional (Fig. 5j) .
We administered the PARP inhibitor AG014699 (ref. 29) to Tet-AIMP2 mice 3 d before injection of AAV1-tTA-IRES-zsGreen and then continuously until the mice were analyzed (Fig. 5a) . AG014699 prevented the degeneration of dopamine neurons in a dose-dependent manner, as monitored by unbiased stereologic counting of tyrosine hydroxylase-and Nissl-positive neurons (Fig. 6a) . AG014699 treatment reduced PARP activation, as monitored by PAR immunoreactivity (Fig. 6b,c) . To evaluate the potential pathophysiologic relevance of PARP1 activation and PAR accumulation in human disease, we monitored PAR by western blot in human postmortem substantia nigra brain tissue from Parkinson's disease patients and age-matched controls (Supplementary Table 1) . It is well known that substantial numbers of dopamine neurons are present in patients with Parkinson's disease 26, 30 , which we confirmed via immunoblot with antibody to tyrosine hydroxylase (Fig. 6d,e) . As previously reported, there was a 2-3-fold increase in AIMP2 levels in the substantia nigra of Parkinson's disease patients as compared with controls, similar to the level of overexpression of AIMP2 that we observed in our models. Accompanying the increase in AIMP2, we observed a ~10-fold increase in PAR levels (Fig. 6d,e) . It has been reported that there is no increase in the level of AIMP2 in areas of the Parkinson's disease brain that are relatively non-affected, such as the cortex 7, 9 . We found no increase in PAR in the cortex of Parkinson's disease patients (Supplementary Fig. 12) , suggesting that the increase in the substantia nigra is a result of the elevation of AIMP2 levels. Taken together, these data suggest that elevation of AIMP2 leads to pathological activation of PARP1 and an accumulation of PAR that results in a loss of dopaminergic neurons (Supplementary Fig. 13 ). This signaling may participate in the disease process of sporadic Parkinson's disease.
DISCUSSION
We found that transgenic expression of the parkin substrate AIMP2 led to age-dependent selective degeneration of dopaminergic neurons in the substantia nigra. Mutations in PARKIN are a common cause of autosomal recessive Parkinson's disease 1,2 . Postmortem studies from sporadic Parkinson's disease have found protein modifications of parkin that lead to its inactivation and the accumulation of the K48 ubiquitinated proteins [6] [7] [8] [9] [10] [11] [12] [13] 18, 31, 32 , such as PARIS, FBP-1 and AIMP2. Thus, parkin inactivation could be a common pathogenic feature in both familial and sporadic Parkinson's disease. Expression of either PARIS or AIMP2 leads to neuronal degeneration 18, 32 . We found that expression of AIMP2 at levels similar to those in observed in Parkinson's disease 7, 9, 18 led to an age-dependent selective neurodegeneration of dopaminergic neurons, which models the human disease. The progressive degeneration of dopaminergic neurons is a characteristic and unique pathological feature of Parkinson's disease 33 . However, npg a r t I C l e S an extensive investigation of the molecular mechanisms underlying neurodegeneration in Parkinson's disease has been hindered by the limited availability of animal models that include age-dependent neurodegeneration 34 . Our conditional AIMP2 transgenic mouse models, in which AIMP2 expression is sustained at levels in dopaminergic neurons similar to those found in sporadic Parkinson's disease, reveal that the canonical nigrostriatal degeneration of human Parkinson's disease can be successfully recapitulated in rodents. The characteristic age-dependent loss of SNpc dopaminergic neurons reached up to 60% at 20 months of age. VTA dopaminergic neurons also degenerated, but to a lesser extent than the SNpc dopaminergic neurons, mirroring human Parkinson's disease 26 . Moreover, striatal dopamine content and the behavior of the transgenic mice corresponded with the deficits in nigral dopamine-producing neurons. The neuronal degeneration in AIMP2 transgenic mice was confined to dopamine neurons in the substantia nigra and VTA when compared with other brain regions such as cortex, which did not develop signs of age-dependent degeneration despite much higher levels of AIMP2. These results suggest that overexpression of AIMP2 leads to selective degeneration of dopamine neurons. Our cell and mouse models provide a unique platform for understanding the cell death signaling events that result in AIMP2-mediated neurodegeneration. In the AIMP2-inducible PC12 cells, toxicity was independent of protein translation efficiency, implicating non-canonical functions of AIMP2 in the execution of the cell death. Pharmacological screening following transient expression of AIMP2 in SH-SY5Y cells identified that AIMP2 toxicity was caspase independent and was mediated by PARP1. Activation of PARP1 typically involves DNA strand nicks and breaks 21, 35 , but AIMP2 seemed to activate PARP1 in the nucleus through a direct protein-protein association, providing a previously unknown mode of PARP1 activation. The dose-dependent protection of dopaminergic neurons against AIMP2 toxicity in mice treated with a PARP1 inhibitor and the complete protection of dopaminergic neurons and prevention of amphetamine-induced stereotypic rotations in Parp1 −/− mice suggest that the suppression of PARP1's enzymatic activity was sufficient to halt the dopaminergic neuronal loss resulting from AIMP2 overexpression. Given that the amphetamine-induced behavior was rescued in Parp1 −/− mice even with AIMP2 induction, AIMP2 accumulation itself does not seem to impair nigrostriatal dopamine release, but rather affects the viability of dopaminergic neurons via PARP1 activation and cell death.
Notably, we found that AAV1-tTA mediated overexpression of AIMP2 at levels equivalent to those produced by CamKIItTA-mediated overexpression in the ventral midbrain of the transgenic mice, and markedly accelerated the pathogenesis of AIMP2-mediated neurodegeneration. The mechanisms underlying the acceleration of the pathogenesis with viral delivery of tTA are not clear. One possibility is the acuteness of the virally induced model, which bypasses compensatory mechanisms, which in many cases are strongly induced during embryonic development 4 . Consistent with this notion, virally induced adult onset deletion of Parkin results in age-dependent degeneration of dopamine neurons 32 , which is absent in germ-line Parkin knockouts 36 . Moreover, viral induction of other Parkinson's disease genes, such as LRRK2 (ref. 37) or α-synuclein 38 , leads to degeneration of dopamine neurons, whereas expression of LRRK2 or α-synuclein via conventional approaches does not cause degeneration of dopamine neurons 39, 40 . Conditional overexpression of α-synuclein via a CamKII-tTA/TetP-α-synuclein expression cassette takes months to cause degeneration of dopamine neurons, whereas viral expression of α-synuclein occurs in a much shorter time frame, similar to our observations 41 . Given that adeno-associated virus serotype 1 transduces both neurons and glia cells 42 , whereas CamKII-tTA/TetP-AIMP2 expression was restricted to neurons, it is possible that the glial expression of AIMP2 accelerates the phenotype.
AIMP2 upregulation is not likely to be the sole mechanism by which inactivation of parkin contributes to the loss of dopamine neurons. How and whether AIMP2 contributes to other touted mechanisms of loss of dopamine neurons resulting from parkin inactivation is not known. These additional mechanisms will need to be evaluated in future studies to determine their relative contributions to dopamine neuron degeneration as a result of parkin inactivation. In particular, it will be important to determine whether AIMP2 and PARIS or other mechanisms of parkin-induced dopamine neurodegeneration intersect in a common pathway or whether they are separate pathways. Given that these other mechanisms may involve perturbations in mitochondrial control, either through PARIS impairment of mitochondrial biogenesis 32 or mitochondrial degradation via mitophagy 43 , it is conceivable that AIMP2 acts downstream of these mitochondrial perturbations. Indeed, under physiological conditions, AIMP2 is trapped in the aminoacyl-tRNA synthetase complex as a structural cofactor in the cytosol and functions to maintain the stability of this complex 44, 45 . Thus, AIMP2 without any stress is only found in the cytosol as a complex with aminoacyl-tRNA synthetase. Dopamine neurons in Parkinson's disease may be particularly vulnerable to oxidative stress 46, 47 , which could account for the AIMP2 elevation and PARP1 activation observed in the substantia nigra of patients with Parkinson's disease, as well as the selective vulnerability of dopamine neurons. Consistent with this notion is the selective degeneration of dopamine neurons in the AIMP2 transgenic mice, as AIMP2 only interacts with and activates PARP1 in dopamine neurons.
In postmortem brain tissue from control and Parkinson's disease patients, there are increased levels of PAR-conjugated proteins in total substantia nigra lysates implicating PARP1 activation in Parkinson's disease pathogenesis. In previous reports, AIMP2 accumulation was noted in familial and sporadic forms of Parkinson's disease in which mutations of PARKIN or loss of function of this E3 ligase have been observed 9, 17, 18 . The presence of AIMP2 accumulation and elevated PARP1 activation in Parkinson's disease patient samples supports the pathological relevance of AIMP2-PARP1 signaling in Parkinson's disease. Consistent with the notion that PARP1 may be involved in Parkinson's disease is the observation that knockout or inhibition of PARP1 is protective against the MPTP model of Parkinson's disease, supporting a role for parthanatos in Parkinson's disease 48, 49 . PARP1 is targetable by drugs and there are many inhibitors of PARP that are undergoing clinical trials for oncologic indications in the treatment of breast, ovarian and prostate cancers 33 . Some of these drugs cross the blood-brain barrier and may potentially be useful in treating Parkinson's disease.
METhODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METhODS
Plasmid constructions. The Tet off transgenic construct (C-terminal FLAG human AIMP2) was cloned into the XhoI site of pPrP.TetP vector 50 (9 kb). pCMVTag2A-AIMP2 (ref. 18 ), EGFP-Parp1 (provided by G.G. Poirier, Laval University), and MYC-AIMP2 (ref. 18 ) and its deletion mutants have been described. Deletion mutants of EGFP-Parp1 (amino acids 1-372 and 1-555) were cloned into the restriction sites (XhoI and XmaI) of EGFP-N1 vector. The GST-AIMP2-FLAG plasmid was generated by using the XhoI restriction site of pGEX-6p1 vector. CBA-pl-WPRE-bGH (5,374 bp) was used to clone the rAAV1-tTA-IRES2-zsGreen viral construct into BamHI/EcoRV sites. The integrity of the cloned constructs was verified by sequencing.
Antibodies. The following antibodies were used. For primary antibodies, we used rabbit antibody to AIMP2 (cat# 10424-1-1AP, 1:1,000 western blot, 1:20,000 TSA immunofluorescence, ProteinTech), rabbit antibody to eGFP (cat# ab290, 1:1,000, Abcam), mouse antibody to MYC (cat# 11 667 149 001, 1:1,000, Roche Diagnostics), mouse antibody to FLAG (M2, 1:5,000, Sigma-Aldrich), mouse and rabbit antibodies to poly(ADP-ribose) (cat# 4335-MC-100 and 4336-BPC-100, Trevigen), antibody to poly(ADP-ribose) polymerase (cat# 556494, mouse, 1:1,000, BD Bioscience; cat# 9542, rabbit, 1:1,000, Cell Signaling), rabbit antibody to tyrosine hydroxylase (NB300-109, 1:2,000, Novus Biologicals), mouse antibody to GFAP (GA5, 1:5,000, Cell Signaling Technology), rabbit antibody to MnSOD (1:5,000, generated as described previously 51 ) and rabbit antibody to MEF2C (cat# 5030, 1:1,000, Cell Signaling). For secondary antibodies, we used horse radish peroxidase (HRP)-conjugated mouse antibody to β-actin (AC15, 1:10,000, Sigma-Aldrich), HRP-conjugated mouse antibody to FLAG (cat# A8592, 1:5,000, Sigma-Aldrich), HRP-conjugated sheep antibody to mouse IgG (cat# RPN4301, 1:5,000, GE Healthcare), HRP-conjugated donkey antibody to rabbit IgG (cat# RPN4101, 1:5,000, GE Healthcare), biotin-conjugated goat antibody to mouse IgG (cat# BA-2000, 1:1,000, Vector Laboratories), biotin-conjugated goat antibody to rabbit IgG (cat# BA-1000, 1:1,000, Vector Laboratories), Alexa Fluor 488-conjugated donkey antibody to mouse or rabbit IgG (H+L) (cat# A21202, A21206, 1:1,000, Invitrogen), Alexa Fluor 568-conjugated donkey antibody to mouse or rabbit IgG (cat# A10037, A10042, 1:1,000, Invitrogen).
conditional AIMP2 transgenic mouse generation. The linearized transgenic constructs (NotI digestion, 7 kbp) were microinjected into the embryos of the B6C3F2 strain and the one-or two-cell embryos were transferred into B6D2F1 pseudopregnant female mice (Transgenic Animal Core of National Cancer Institute). Using genomic DNA prepared from tail snip (Proteinase K, Roche Diagnostics; direct PCR (tail) Lysis, Viagen), pups were genotyped by PCR (GoTaq Green Master Mix, Promega) using TetP-AIMP2 primers (forward: CGG GTC GAG TAG GCG TGT AC; reverse: TCT AGA TGA TCC CCG GGT ACC GAG; PCR product = 173 bp) to select positive founders. Positive founders were further subjected to semiquantitative PCR and normalized by GAPDH PCR (forward: AAA CCC ATC ACC ATC TTC CAG; reverse: AGG GGC CAT CCA CAG TCT TCT; PCR product = 300 bp) to screen for high copy-number founders. The top three high copy founders were mated with C57/BL6 mice for two-three generations to establish the transgenic lines. The following primer sets were used for genotyping of CamKIIα-tTA (forward: TGA AAG TGG GTC CGC GTA C; reverse: TAC TCG TCA ATT CCA AGG GC; PCR product = 391 bp) or Parp1 (primer 1: AGG TGA GAT GAC AGG AGA TC; primer 2: CCA GCG CAG CTC AGA GAA GCC A; primer 3: CAT GTT CGA TGG GAA AGT CCC; PCR products: null = 350 bp, wild type = 112 bp). AIMP2 induction in conditional transgenic mice was suppressed by feeding the mice with doxycycline-containing food (doxycycline Diet-Sterile, 200 mg per kg doxycycline, Bio-Serv). All procedures involving mice were approved by and conformed to the guidelines of the Institutional Animal Care Committee of the Johns Hopkins University. Mice were kept in a 12-h dark, 12-h light cycle.
Immunohistochemistry (tyrosine hydroxylase, AImP2 and gFAP) and stereological assessment of the number of tyrosine hydroxylase-and nisslpositive cells. Mice were intracardially perfused with ice-cold phosphatebuffered saline (PBS) and 4% paraformaldehyde/PBS (wt/vol, pH 7.4) after deep anesthesia by intraperitoneal injection of Nembutal sodium solution (50 µl of twofold dilution in PBS of pentobarbital sodium 50 mg ml −1 , Lundbeck). Brains were removed and postfixed 16 h in the same fixative. After cryoprotection in 30% sucrose/PBS (wt/vol, pH 7.4), brains were frozen on dry ice, and serial coronal sections (40-µm sections) were cut with a microtome, and the striatum and ventral midbrain regions were saved. Every four sections were collected for subsequent procedures. Free-floating sections in one group were blocked with 4% goat serum (vol/vol, Sigma-Aldrich)/PBS plus 0.2% Triton X-100 (vol/vol) and incubated with antibodies to tyrosine hydroxylase, AIMP2 or GFAP, followed by incubation with biotin-conjugated antibody to rabbit (tyrosine hydroxylase and AIMP2) or mouse (GFAP), ABC reagents (Vector Laboratories) and Sigmafast 3,3′-diaminobenzidine (DAB) tablets (Sigma-Aldrich). Sections were counterstained with Nissl (0.09% thionin, wt/vol) after tyrosine hydroxylase staining as described previously 32 . Sections were dehydrated in 100% ethanol and cleared in Xylene (Fisher Scientific) followed by mounting with DPX (Sigma-Aldrich) before imaging under a microscope. Cell counting was performed with the aid of the optical fractionator software, which is an unbiased method for the counting of tyrosine hydroxylase-positive or Nissl-positive cells in the substantia nigra region of the left hemisphere of AIMP2 transgenic mice (experimenters were blinded for genotypes of mice during stereological counting) or in the injected and non-injected sides of mice used in the virus-injection procedure. This unbiased stereological counting was done with a computer-assisted image analysis system consisting of an Axiophot photomicroscope (Carl Zeiss Vision) equipped with a computer-controlled motorized stage (Ludl Electronics), a Hitachi HV C20 video camera and Stereo Investigator software (MicroBrightField). The total numbers of tyrosine hydroxylase-and Nissl-stained neurons were calculated as previously described 52 .
Immuofluorescence. 4% paraformaldehyde/PBS (pH 7. co-immunoprecipitation and immunoblot analysis. Human brain tissue or mouse brains or cells were homogenized and prepared in lysis buffer (for tissue, 10 mM Tris-HCl (pH 7.3), 150 mM NaCl, 5 mM EDTA, 1% Nonidet P-40 (vol/vol), 1% Triton X-100, 0.5% sodium deoxycholic acid (wt/vol); for cells, PBS, 1% Nonidet P-40 supplemented with Phosphatase Inhibitor Cocktail I and II (P2850 (I), P5726 (II), Sigma-Aldrich) and Complete Protease Inhibitor Mixture). Protein levels were quantified using a BCA protein assay kit (Pierce). Coimmunoprecipitation was performed with antibodies and Protein G Sepharose and Glutathione Sepharose 4B (GE Healthcare Sciences). The immunocomplexes were then washed with immunoprecipitation buffer four times and samples were prepared by adding 2× sample loading buffer (Bio-Rad). Brain tissue lysates (40 µg) or immunoprecipitated samples were electrophoresed on SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were blocked with 5% skim milk (wt/vol) in TBS-T and incubated with primary antibodies. After HRPconjugated secondary antibody incubation, the immunoblot signal was detected using chemiluminescent substrates (Thermo Scientific). Subcellular fractionation. Ventral midbrain tissues from mice or ice-cold PBSwashed SH-SY5Y cells were homogenized in a hypotonic buffer (10 mM HEPES (pH 7.5), 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM DTT and 0.1% NP-40) supplemented with a complete protease inhibitor cocktail and passed through 26G syringe needle three times. After incubation on ice for 20 min with 10 s of vortexing twice, the lysates were centrifuged at 720g for 5 min. The supernatant was used as a postnuclear fraction and the pellet was washed with the same buffer twice and used as a nuclear fraction for subsequent western blot analysis (loading for western blot: 2% of postnuclear fraction and 8% of nuclear fraction). npg measurement of neurotransmitters in the striatum. Biogenic amine concentrations were measured by HPLC with electrochemical detection (HPLC-ECD). Briefly, mice were decapitated and the striatum was quickly removed. Striatal tissue was weighed and sonicated in 0.2 ml of ice-cold 0.01 mM perchloric acid containing 0.01% EDTA (wt/vol) and 60 nM 3,4-dihydroxybenzylamine (DHBA) as an internal standard. After centrifugation (15,000g, 30 min, 4 °C), the supernatant was passed through a 0.2-µm filter. 20 µl of the supernatant were analyzed in the HPLC column (4.6 × 150 mm C-18 reverse phase column, MC Medical) with detection by a dual channel Coulchem III electrochemical detector (Model 5300, ESA). The protein concentrations of tissue homogenates were measured using the BCA protein assay kit (Pierce). Data were normalized to protein concentrations (ng neurotransmitters per mg tissue).
Stereotaxic intranigral virus injection. For stereotaxic injection of AAV1-IRESzsGreen-overexpressing tTA and zsGreen, 8-week-old mice of indicated genotypes were anesthetized with pentobarbital (60 mg per kg). An injection cannula (26.5 gauge) was applied stereotaxically into the SNpc (anteroposterior, 3.2 mm from bregma; mediolateral, 1.3 mm; dorsoventral, 4.3 mm) or the cortex (anteroposterior, 3.2 mm; mediolateral, 2 mm; dorsoventral, 0.5 mm) unilaterally (applied into the right hemisphere). The infusion was performed at a rate of 0.2 µl per min, and 2 or 1 µl of a high-titer AAV1-tTA-IRES-zsGreen (3.5 × 10 13 AAV vector genomes per ml in PBS) was injected into each mouse. After the final injection, the injection cannula was maintained in the substantia nigra for an additional 5 min for a complete absorption of the virus and then slowly removed from the mouse brain. The head skin was closed by suturing, and wound healing and recovery were monitored following surgery. For western blot analysis, brains were removed 17 d (nigral injection) or 25 d (cortical injection) after viral injection and protein samples were prepared as noted above. For stereological analysis, mice were perfused and fixed intracardially with ice-cold PBS followed by 4% paraformaldehyde 25 d after intranigral viral injection. The brain was removed and processed for immunohistochemistry or immunofluorescence. Amphetamine-induced stereotypic rotation was performed 3 weeks after the unilateral intranigral virus injection. PARP1 inhibition was accomplished by AG014699 (PF-01367338, Selleck Chemicals) treatment (no randomization was used in the drug treatment protocol) that was initiated 3 d before intranigral AAV-tTA injection and continued until perfusion.
Behavioral tests. All behavior tests were performed in the Behavioral Core Facility at the Johns Hopkins University School of Medicine. Because behavioral data for open field and rotarod tests were obtained automatically using instruments detailed below, no particular blinding strategy was employed. open field test. General locomotor and exploratory activities were assessed in open field square-shaped chambers equipped with an automated beam tracking system. Unless otherwise noted, the tests were performed in the afternoon. Briefly, a mouse was placed in the center of the open field arena and allowed to explore the area for a total of 30 min. The activities of a mouse were recorded over 30 min, which consisted of six 5-min sessions, by photobeam activity system software installed in a computer connected to the open field equipment. Before and after each testing, the surface of the arena was cleaned with 70% ethanol. The total number of beam breaks during the 30-min period was used to determine gross locomotor activity of a mouse. These mice were also used for rotarod testing.
Rotarod test. Motor coordination of mice was measured as the retention time on an accelerating rotarod of the rotamex V instrument equipped with photobeams and a sensor to automatically detect mice that fell from the rotarod. Prior to the actual rotarod test, mice were trained on the rotarod at 4.0 r.p.m. for 5 min and allowed to rest for at least 30 min. After training and resting, four mice were placed on separate rods and the durations on the accelerating rods were recorded automatically by the software installed on a computer connected to the instrument. The setting of the rotamex was as follows and remained constant throughout all trials. Start speed, 4.0 r.p.m.; maximum speed, 40 r.p.m.; acceleration interval, 30 s; acceleration step, 4 r.p.m. The tests were repeated three times and the average retention time and end speed were recorded for each mouse. The retention time was used to determine the motor coordination of the mouse.
Amphetamine induced stereotypic rotation. 25 d after mice received the AAV1-tTA (2 µl) intranigral injection into the right hemisphere, we intraperitoneally administered 5 mg per kg amphetamine (Sigma-Aldrich). Mice were placed into a white paper cylinder of 20-cm diameter and monitored for 30 min. The behavior of mice was filmed at three 1-min intervals between 20 and 30 min following amphetamine administration. Full body ipsilateral rotations (clockwise) during 1-min sessions were counted for each mouse from the video recordings.
In vitro binding assay of recombinant AImP2. The GST fusion protein, GST-AIMP2, was prepared following a standard protocol and GST was cleaved by prescission protease (GE Healthcare). For in vitro binding assays, recombinant AIMP2 was incubated with immunoprecipitated human PARP1 from SH-SY5Y using a PARP1-specific antibody and protein G beads. After washing three times with a binding buffer (1% Triton X-100 in PBS), the bound proteins were separated by SDS-PAGE and immunoblotted with the indicated antibodies. Antibody to FLAG pulldown was performed by incubating recombinant AIMP2-FLAG and recombinant PARP1 with protein G sepharose beads overnight at 4 °C using a similar procedure as described for the anti-PARP1 pulldown.
cell culture and transfection. SH-SY5Y cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (vol/vol) and 100 U per ml of penicillin/streptomycin antibiotics and were grown at 37 °C, 7% CO 2 , and 90% humidity. AIMP2-inducible tet-off PC12 cell lines were maintained in DMEM supplemented with 10% horse serum, 5% tet-approved fetal bovine serum (Clontech) and the following antibiotics: 100 U per ml penicillin/ streptomycin (Invitrogen), 100 µg per ml G418 (Invitrogen), 200 µg per ml hygromycin (Invitrogen) and 200 ng per ml doxycycline (Invitrogen) for suppression of AIMP2 induction. For differentiation, PC12 cells were passed onto collagencoated plates and provided with 100 ng ml −1 nerve growth factor (NGF, Roche) in low serum media (1% horse serum (vol/vol) in DMEM). NGF was replenished every other day during differentiation. All transient transfections of SH-SY5Y cells were performed using Fugene transfection reagent (Roche). Cruz Biotechnology), trypan blue exclusion was performed to assess cell toxicity by counting the number of dead (blue) and live cells. After the indicated days of differentiation and induction, cultures were briefly washed with PBS, followed by trypsinization. Resuspended cells were mixed with equal volume of 0.4% trypan blue (wt/vol). Live and dead cells were counted under light microscope using a hemacytometer.
35 S-pulse methionine incorporation assay. Differentiated AIMP2-inducible PC12 cells grown in regular media were pulse incubated in media containing 35 S-labeled methionine together with appropriate chemicals such as 1-methyl-4-phenylpyridinium (MPP + ), H 2 O 2 and thapsigargin (all purchased from Sigma-Aldrich). After 10-min incubation, total lysates were prepared and separated in SDS-PAGE followed by transferring to nitrocellulose membrane and taking signals in X-ray film to visualize newly synthesized proteins with 35 S-methionine incorporation.
In vitro PARP1 activity assay. In vitro PARP1 activity assay was performed following the manufacturer's instructions (Trevigen, Universal PARP Colorimetric Assay Kit). As a modification, activated DNA was left out of the reactions to prevent PARP1 activation saturation. Briefly, GST and GST-tagged recombinant AIMP2 were added to different units of recombinant PARP1 in histonecoated wells. After reaction for 60 min at (15-25 °C) , the levels of PARsylation of the PARP1 substrate histone were measured using a colorimetric assay (absorbance at 450 nm) and normalized as fold change compared to the level at 0.125 units of PARP1 with GST.
Statistics. Power analysis was performed by using G*Power 3.1 software to determine approximate sample sizes for behavior tests or tyrosine hydroxylase stereological analysis of Camk2a-tTA; TetP-AIMP2 mice and AAV-tTA virus injection mice. On the basis of mean difference from our preliminary experiments with npg co r r i G e n Da Corrigendum: Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss 
